玻璃体腔注射抗血管内皮生长因子药物对眼压的真实世界影响:基于IRIS登记数据库的分析
基于美国眼科学会IRIS登记数据库,纳入23776例仅接受一种抗血管内皮生长因子(VEGF)药物(贝伐珠单抗、阿柏西普或雷珠单抗)右眼注射的患者,比较注射眼与未治疗对侧眼的眼压变化。结果显示注射眼眼压平均降低0.9 mmHg,对侧未治疗眼平均降低0.2 mmHg,差异有统计学意义;临床显著眼压升高在注射眼为2.6%,对侧未治疗眼为1.5%,但阿柏西普组未见此类升高。
要点
- 抗VEGF玻璃体腔注射与眼压小幅但统计学显著的下降相关,注射眼平均降0.9 mmHg,对侧未治疗眼平均降0.2 mmHg。
- 临床显著眼压升高(持续升高至少6 mmHg且眼压超过21 mmHg)总体发生率为注射眼2.6% vs 对侧未治疗眼1.5%。
- 贝伐珠单抗和雷珠单抗组临床显著眼压升高显著高于对侧未治疗眼,阿柏西普组则无显著差异。
核心结论
- 真实世界数据表明抗VEGF玻璃体腔注射与眼压随时间小幅但统计学显著的下降相关。
- 平均2.6%的注射眼出现持续临床显著眼压升高,对侧未治疗眼为1.5%,但阿柏西普未见此类升高。
研究设计与样本
- 数据库研究,纳入美国眼科学会IRIS登记数据库中23776例仅右眼接受一种抗VEGF药物(贝伐珠单抗、阿柏西普或雷珠单抗)注射的独特患者。
- 亚组包括仅患年龄相关性黄斑变性的患者以及研究前至少1年未接受抗VEGF注射的患者。
- 分析接受至少12、18和25次注射的患者,并采用对侧未治疗眼作为对照。
主要发现
- 所有药物组患者眼压均较基线下降,注射眼平均下降0.9 mmHg,对侧未治疗眼平均下降0.2 mmHg,差异有统计学意义。
- 在大多数亚组中,校正混杂因素的广义线性模型显示贝伐珠单抗与阿柏西普和雷珠单抗相比眼压降低幅度略小。
- 临床显著眼压升高在注射眼为2.6%,对侧未治疗眼为1.5%。
- 临床显著眼压升高发生率:阿柏西普1.9%、雷珠单抗2.8%、贝伐珠单抗2.8%;贝伐珠单抗和雷珠单抗显著高于对侧未治疗眼,阿柏西普则无显著差异。
关键数值与推荐
- 临床显著眼压升高定义为持续升高至少6 mmHg且眼压超过21 mmHg。
- 主要结局指标为至少随访1年时眼压较基线的平均变化,以及临床显著眼压升高的眼比例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify sustained differences in intraocular pressure (IOP) after intravitreous injections of anti-vascular endothelial growth factor (VEGF) drugs. DESIGN: Database study. PARTICIPANTS: Patients seeing an ophthalmic provider who contributes to the database. METHODS: We identified a total of 23 776 unique patients who received only a single type of anti-VEGF medication (bevacizumab, aflibercept, or ranibizumab) by injection in the right eye in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Subgroups included patients with age-related macular degeneration only and patients who had not received an anti-VEGF injection for at least 1 year before the study. We examined those with at least 12, 18, and 25 injections for each of these 3 medications. For all groups, we used fellow, untreated eyes for comparison. MAIN OUTCOME MEASURES: The mean change in IOP from baseline at a minimum of 1 year of follow-up and the proportion of eyes with a clinically significant IOP increase (defined as sustained rise of at least 6 mmHg to an IOP of more than 21 mmHg). RESULTS: All patients in all groups receiving all drugs showed a decrease in IOP from baseline, with a mean of 0.9 mmHg in treated eyes compared with an average decrease of 0.2 mmHg in fellow untreated eyes, a statistically significant difference. A generalized linear model accounting for confounders associated bevacizumab with slightly less lowering of IOP than aflibercept and ranibizumab in most subgroups. A clinically significant IOP increase was seen in 2.6% of eyes receiving injections compared with 1.5% in the associated untreated fellow eyes. Clinically significant IOP increases occurred at a rate of 1.9%, 2.8%, and 2.8% for aflibercept, ranibizumab, and bevacizumab, respectively, which was significantly higher than untreated fellow eyes for bevacizumab and ranibizumab, but not for aflibercept. CONCLUSIONS: These analyses from real-world data indicate that anti-VEGF intravitreous injections are associated with a small but statistically significant decrease in IOP over time. A proportion of patients, on average 2.6%, experienced a sustained clinically significant IOP rise with these drugs overall compared with 1.5% in the fellow untreated eyes. However, such an increase was not seen with aflibercept.
引用
- Atchison EA, Wood KM, Mattox CG, et al. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry. Ophthalmology. 2018. PMID: 29336897. doi:10.1016/j.ophtha.2017.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。